Status epilepticus is the leading neurological emergency in children, with mortality 2-7% and significant morbidity (10-20%). It is defined as the occurrence of a crisis lasting more than 5 minutes and requiring the implementation of treatment to stop it and thus limit the immediate and long-term consequences. The research hypothesis is that LEVETIRACETAM is non-inferior to PHENYTOIN in terms of cessation and absence of recurrence of status epilepticus, with better clinical tolerance in children from 3 months to 17 years old, with or without epileptic disease, with or without a history of status epilepticus
Study Type
OBSERVATIONAL
Enrollment
151
Service pédiatrie 1 - CHU de Strasbourg - France
Strasbourg, France
Highlight non-inferiority of LEVETIRACETAM compared to PHENYTOIN
The non-inferiority of LEVETIRCETAM in comparison with PHENYTOIN is based on a composite primary endpoint consisting of the total duration of the seizure, the need for another antiepileptic treatment to resolve the seizure or recurrence within 24 hours. following the start of treatment for a new status epilepticus and the total duration of hospitalization. The need for another antiepileptic drug or recurrence is a binary variable with presence (= yes = 1) or absence (= no = 0). The total duration of the crisis is expressed in minutes, and corresponds to the interval between the identification of the event and the objectification of its cessation. The total duration of hospitalization is expressed in days, and corresponds to the duration between the first day of hospitalization (regardless of the location) and the day of discharge (regardless of the department).
Time frame: Up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.